CorMedix Conference Call Summary Company Overview - **Company**: CorMedix - **Focus**: Transitioned from a single product company (DefenCath) to a diversified specialty pharmaceutical company post-acquisition of Melinta in 2025, focusing on institutional settings of care with a portfolio primarily of injectable anti-infective drugs [3][4] Strategic Focus Areas - **Current Strategy**: Aiming to diversify beyond renal space and focus on various therapeutic areas within institutional care settings [4] - **Development Pipeline**: - **REZZAYO**: In phase 3 studies for prophylaxis of invasive fungal infections, with data readout expected in mid-to-late second quarter [4] - **DefenCath**: In phase 3 for prevention of CLABSI in patients receiving total parenteral nutrition (TPN), targeted for completion in early 2027 [5] Key Product Insights - **DefenCath**: - Demonstrated a 70% reduction in CRBSIs and hospitalizations in clinical studies [7][8] - Unique reimbursement model (TDAPA) allows for a two-year window for buy and bill reimbursement, transitioning to bundled payments [9] - Focus on stabilizing patient utilization and growth strategies for Medicare Advantage patients [10][16] - **REZZAYO**: - Long-acting echinocandin with a total addressable market of $250-$350 million, currently indicated for treatment of Candida infections [24] - Differentiation potential in prophylaxis against invasive fungal disease, with a focus on reducing drug-drug interactions and hepatotoxicity compared to standard care [26][40] Market Opportunities - **DefenCath in TPN**: Addressable market estimated at $500-$750 million, with high unmet needs in infection prevention for patients on TPN [46][47] - **REZZAYO Prophylaxis**: Potential market size of $500 million for allogeneic bone marrow transplant patients, with additional opportunities in solid organ transplants [40][41] Financial Position - **Cash Position**: Approximately $150 million in cash with zero net debt, expected to generate cash flow through 2026 [55] - **Stock Buyback**: Announced a $70 million stock repurchase program to enhance shareholder value [55] Contracting and Reimbursement Strategy - **Dialysis Operators**: Agreements structured to accommodate potential reimbursement challenges during the TDAPA transition [63] - **Medicare Advantage**: Early discussions ongoing, with expectations for positive payer feedback [43] Investor Insights - **Market Valuation**: Currently valued at 4.5x forward EBITDA, significantly below peers (9x-14x), indicating potential undervaluation of REZZAYO and DefenCath [68] - **Future Growth Catalysts**: Anticipated updates on clinical data and market strategies expected to align company valuation with operational strength [68] Conclusion - CorMedix is positioned for growth with a diversified product pipeline and strategic focus on institutional care settings. The upcoming clinical data for REZZAYO and DefenCath, along with a solid financial foundation, presents a compelling investment opportunity.

Financial Data and Key Metrics Changes - In Q4 2025, net revenue reached $128.6 million, a significant increase from $31.2 million in Q4 2024, primarily driven by DefenCath's contribution of $91.2 million and Melinta's contribution of $37.4 million [16] - For the full year 2025, total revenue on a pro forma basis was $401.3 million, aligning with previously established guidance [16] - The company reported a net income of $14 million in Q4 2025, impacted by a tax expense of $42.4 million, mostly non-cash [18] - Adjusted EBITDA for Q4 was $77.2 million, reflecting modest growth quarter-over-quarter [19] - Cash and cash equivalents at the end of Q4 were $148.5 million, supported by strong operating cash flow of nearly $100 million during the quarter [20] Business Line Data and Key Metrics Changes - DefenCath generated $258.8 million in net sales for the full year 2025, with peak sales of just under $260 million achieved [5][16] - The Melinta portfolio contributed $37.4 million in Q4 2025, marking the first full reporting period post-acquisition [16] - Operating expenses in Q4 2025 were $48.2 million, up from $17.1 million in the prior year, reflecting the expanded cost structure due to the Melinta acquisition [17] Market Data and Key Metrics Changes - The company is focusing on maintaining patient utilization rates for DefenCath in outpatient hemodialysis as it transitions to a bundled add-on reimbursement model starting July 1, 2026 [6] - The estimated market opportunity for REZZAYO is approximately $2.5 billion across its indications, while DefenCath and TPN are estimated between $500 million and $750 million [9] Company Strategy and Development Direction - The company aims to achieve a target synergy of $35 million from the Melinta acquisition during Q4 2025 and is focused on integrating operations for long-term sustainable growth [5] - CorMedix is actively engaging with multiple Medicare Advantage providers and new potential customers for DefenCath, REZZAYO, MINOCIN, and BAXDELA [8] - The company has announced a share repurchase program, indicating confidence in its financial flexibility and growth potential [21] Management's Comments on Operating Environment and Future Outlook - Management views 2025 as a transformational year and anticipates 2026 to be transitional, setting the stage for long-term growth in 2027 and beyond [21] - The company is optimistic about the potential for increased Medicare provider reimbursement in 2027, which could lead to a higher net selling price for DefenCath [7] - Management is confident in the outlook for 2026 and the path to future growth and sustained profitability [21] Other Important Information - The company completed its first analyst R&D day, focusing on educating stakeholders about the market opportunity for REZZAYO and its pipeline assets [9] - The Nutriguard clinical study for DefenCath is approximately 30% enrolled, with completion anticipated in early 2027 [14] Q&A Session Summary Question: Update on dialysis customer conversations regarding DefenCath - Management indicated that conversations are progressing well, focusing on preserving patient utilization and negotiating pricing structures for 2026 and 2027 [23] Question: Clinical significance of REZZAYO phase III data - Management highlighted the importance of various success metrics in the data, which will guide marketing strategies and discussions with payers [24][25] Question: Developments on TDAPA extension bills - Management noted that timing is uncertain due to legislative complexities and current global events, but they are actively working on the issue [29][30] Question: Inpatient opportunity with DefenCath and Melinta product portfolio - Management discussed the current customer mix and potential growth opportunities, emphasizing the importance of onboarding additional customers [33][41]

Financial Data and Key Metrics Changes - In Q4 2025, net revenue reached $128.6 million, a significant increase from $31.2 million in Q4 2024, primarily driven by DefenCath's contribution of $91.2 million and Melinta's contribution of $37.4 million [16][17] - For the full year 2025, total revenue on a pro forma basis was $401.3 million, aligning with previously established guidance [16] - The company reported a net income of $14 million in Q4 2025, impacted by a tax expense of $42.4 million, mostly non-cash [18][19] - Adjusted EBITDA for Q4 was $77.2 million, reflecting modest growth quarter-over-quarter [19][20] - Cash and cash equivalents at the end of Q4 were $148.5 million, supported by strong operating cash flow of nearly $100 million during the quarter [20] Business Line Data and Key Metrics Changes - DefenCath generated $258.8 million in net sales for the full year 2025, with peak sales of just under $260 million achieved [5][16] - The Melinta portfolio contributed $37.4 million in Q4 2025, marking its first full reporting period post-acquisition [16] Market Data and Key Metrics Changes - The company anticipates a revenue concentration for DefenCath to be front-loaded in the first half of 2026, with expected price erosion in the latter half due to the transition to a bundled add-on reimbursement mechanism [6][7] - The estimated market opportunity for REZZAYO is approximately $2.5 billion across its indications, while DefenCath and TPN are estimated between $500 million and $750 million [9] Company Strategy and Development Direction - The company is focused on maintaining patient utilization rates for DefenCath and negotiating pricing structures for 2026 and 2027 [6][7] - The acquisition of Melinta Therapeutics is seen as a strategic move to enhance growth, with a focus on integrating operations and achieving synergies [5][10] - The company is actively pursuing discussions with Medicare Advantage providers and new customers for DefenCath [8] Management's Comments on Operating Environment and Future Outlook - Management views 2025 as a transformational year and expects 2026 to be transitional, setting the stage for long-term sustainable growth [21] - The company remains confident in its financial flexibility and commercial momentum, positioning itself for both organic and inorganic growth opportunities [21] Other Important Information - The company completed its first analyst R&D day, focusing on educating stakeholders about the market opportunity for REZZAYO and its pipeline assets [8][9] - The phase 3 ReSPECT study for REZZAYO is on track for top-line data release in Q2 2026 [11][12] Q&A Session Summary Question: Update on dialysis customer conversations regarding DefenCath pricing - Management indicated that conversations are progressing well, focusing on preserving patient utilization and negotiating pricing structures for 2027 [23] Question: Clinical significance of REZZAYO phase 3 data - Management highlighted the importance of pathogen data and secondary endpoints in guiding commercial utility and marketing strategies [24][25] Question: Developments on TDAPA extension bills - Management noted that timing is uncertain due to legislative complexities and current global events, but they are actively working on the issue [29][30] Question: Inpatient opportunity with DefenCath and Melinta product portfolio - Management discussed the current customer mix and potential growth opportunities, emphasizing the importance of onboarding new customers [33][41]

Financial Data and Key Metrics Changes - In Q4 2025, net revenue reached $128.6 million, a significant increase from $31.2 million in Q4 2024, primarily driven by DefenCath's contribution of $91.2 million and Melinta's portfolio contribution of $37.4 million [16][17] - For the full year 2025, total revenue on a pro forma basis was $401.3 million, aligning with previously established guidance [16] - The company reported a net income of $14 million in Q4 2025, impacted by a tax expense of $42.4 million, mostly non-cash [18][19] - Adjusted EBITDA for Q4 was $77.2 million, reflecting modest growth quarter-over-quarter [19] Business Line Data and Key Metrics Changes - DefenCath generated $258.8 million in net sales for the full year 2025 [17] - The operating expenses for Q4 2025 were $48.2 million, up from $17.1 million in the prior year, reflecting the expanded cost structure post-Melinta acquisition [17] Market Data and Key Metrics Changes - The company is focusing on maintaining patient utilization rates for DefenCath in outpatient hemodialysis, especially as reimbursement transitions to a bundled add-on mechanism starting July 1, 2026 [6][7] - The guidance for DefenCath in 2026 is set at $150 million-$170 million, with 2027 guidance at $100 million-$125 million [6][8] Company Strategy and Development Direction - The acquisition of Melinta Therapeutics is seen as a significant growth opportunity, adding durable products like MINOCIN and VABOMERE to the portfolio [11] - The company is actively pursuing discussions with Medicare Advantage providers and new customers for DefenCath, REZZAYO, MINOCIN, and BAXDELA [9] - 2026 is expected to be a transitional year, with a focus on new catalysts and value drivers, particularly the phase 3 ReSPECT data for REZZAYO [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the post-TDAPA environment and maintain growth through strategic pricing and customer negotiations [6][23] - The company is optimistic about the potential for increased Medicare provider reimbursement in 2027, which could lead to a higher net selling price [7] Other Important Information - The company has expanded its workforce significantly, growing from approximately 100 to just under 200 employees, to support growth and operational needs [17] - The company has initiated a share repurchase program, indicating confidence in its financial position and future growth prospects [21] Q&A Session Summary Question: Update on dialysis customer conversations and pricing for DefenCath - Management indicated that conversations are progressing well, focusing on preserving patient utilization and negotiating pricing structures for 2026 and beyond [23] Question: Clinical significance of REZZAYO phase 3 data - Management highlighted that the data will guide commercial utility and marketing strategies, with a focus on pathogen data and secondary endpoints [24][25] Question: Developments on TDAPA extension bills and partnerships - Management noted ongoing efforts with legislators and other companies, but timing remains uncertain due to external factors [29][30] Question: Inpatient opportunity with DefenCath and Melinta product growth - Management discussed the current customer mix and potential growth from mid-sized operators, emphasizing the importance of onboarding new customers [33][41]

Core Insights - CorMedix Inc. reported a net revenue of $128.6 million for Q4 2025, with a full-year pro forma revenue of $401.3 million, reflecting significant growth compared to the previous year [1][4][8] - The company achieved a net income of $14.0 million in Q4 2025, with an adjusted EBITDA of $77.2 million, indicating strong operational performance [1][7][8] - CorMedix is focused on expanding patient access to its product DefenCath and has completed the acquisition of Melinta, which is expected to enhance its product portfolio [3][4] Financial Highlights - Q4 2025 net revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio, marking an increase from $31.2 million in Q4 2024 [4][5] - Total operating expenses for Q4 2025 were $48.2 million, a significant increase from $17.1 million in Q4 2024, primarily due to the Melinta acquisition and associated costs [5][9] - For the full year 2025, CorMedix reported total revenue of $311.7 million, with net sales of DefenCath at $258.8 million and net revenue from Melinta at $52.9 million [8][9] Operational Developments - The company has initiated a share repurchase program authorizing up to $75 million of its common stock [5] - CorMedix anticipates clinical data from the Phase 3 ReSPECT study of REZZAYO in Q2 2026, which is crucial for its growth strategy [5][14] - The ongoing Phase 3 study of taurolidine/heparin catheter lock solution in TPN patients is expected to complete enrollment in the first half of 2027 [5][14] Cash Position - As of December 31, 2025, CorMedix had cash and short-term investments totaling $148.5 million, excluding restricted cash [10][22]

Core Insights - CorMedix Therapeutics will report its financial results for Q4 and full year 2025 on March 5, 2026, before market opens and will host a corporate update conference call at 8:30 AM ET [1][2] Company Overview - CorMedix Therapeutics is focused on developing and commercializing therapeutic products for life-threatening diseases and conditions [3] - The company is commercializing DefenCath for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis [3] - Following the acquisition of Melinta Therapeutics in August 2025, CorMedix is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV™, BAXDELA, and KIMYRSA [3] Clinical Studies and Developments - CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations [4] - The company intends to develop DefenCath as a catheter lock solution for other patient populations [4] - REZZAYO is approved for treating candidemia and invasive candidiasis in adults, with a Phase III study ongoing for prophylaxis of invasive fungal disease in adult patients undergoing allogeneic bone marrow transplantation, with topline results expected in Q2 2026 [4]

Core Viewpoint - CorMedix Therapeutics has announced a share repurchase program authorizing the repurchase of up to $75 million of its outstanding common stock, effective through December 31, 2027 [1] Financial Position - The company has a strong balance sheet with approximately $150 million in cash and cash equivalents as of December 31, 2025, and 79.3 million common shares outstanding [2] - The share repurchase program is seen as a disciplined way to return value to shareholders while maintaining financial flexibility for business investments [2] Share Repurchase Program Details - Repurchases may occur at management's discretion through various methods, including privately negotiated transactions, block trades, and open market purchases [3] - The program is subject to market conditions, liquidity, cash flow considerations, and applicable securities laws [3] - There is no obligation for CorMedix to repurchase any specific amount of shares, and the program may be suspended or discontinued at any time [3] Company Overview - CorMedix is focused on developing and commercializing therapeutic products for life-threatening conditions, including the commercialization of DefenCath for preventing catheter-related bloodstream infections [4] - Following the acquisition of Melinta Therapeutics LLC in August 2025, CorMedix is also commercializing a portfolio of anti-infective products [4] Clinical Development - CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition and Pediatric Hemodialysis populations, with plans to develop it as a catheter lock solution for other patient populations [5] - REZZAYO is approved for treating candidemia and invasive candidiasis in adults, with a Phase III study ongoing for prophylaxis of invasive fungal disease in adult patients undergoing allogeneic bone marrow transplantation, with topline results expected in Q2 2026 [5]

Core Insights - CorMedix Therapeutics has announced changes in its executive leadership, with CEO Joseph Todisco extending his contract and taking on the role of Chairman of the Board, succeeding Myron Kaplan, who will become the Lead Independent Director [1][2][3] Leadership Changes - Joseph Todisco's extended contract reflects his long-term commitment to CorMedix, and his transition to Chairman is seen as a strategic move to strengthen the company for future success [1][2] - Mike Seckler has been appointed as EVP & Chief Commercial Officer, bringing extensive experience in hematology and oncology, previously serving as CEO of Evome Medical Technologies Inc. [2][3] Company Overview - CorMedix is focused on developing and commercializing therapeutic products for life-threatening conditions, including its product DefenCath, which is aimed at preventing catheter-related bloodstream infections in hemodialysis patients [4] - Following the acquisition of Melinta Therapeutics LLC in August 2025, CorMedix is also commercializing a range of anti-infective products, including MINOCIN, REZZAYO, VABOMERE, ORBACTIV™, BAXDELA, and KIMYRSA [4] Clinical Developments - CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition and Pediatric Hemodialysis populations, with plans to develop it as a catheter lock solution for other patient groups [5] - REZZAYO is currently approved for treating candidemia and invasive candidiasis in adults, with a Phase III study ongoing for prophylaxis of invasive fungal disease in patients undergoing allogeneic bone marrow transplantation, with topline results expected in Q2 2026 [5]

Core Insights - CorMedix Inc. is addressing a significant unmet medical need in preventing dialysis-related bloodstream infections through its catheter lock solution, DefenCath, which has shown promising clinical results [2][3] Group 1: Product Development and Clinical Results - DefenCath has demonstrated a 72% reduction in catheter-related bloodstream infections and a 70% reduction in related hospitalizations based on real-world evidence from a study ongoing since mid-2024 [3] - The adoption of DefenCath is exceeding expectations, with utilization rates well above the target of 6,000 patients [4] Group 2: Financial Performance and Growth Opportunities - CorMedix reported approximately $13 million in sales from Melinta Therapeutics' portfolio in September, indicating potential for significant synergies and growth opportunities outside the hemodialysis space [5] - The company is finalizing supply pricing under existing contracts and aims to boost utilization among Medicare Advantage users in the upcoming months [5] Group 3: Future Prospects - CorMedix is preparing for add-on periods beginning in summer 2026 and anticipates Phase III trial data for its other leading candidate, REZZAYO, in early 2026 [6]

Core Insights - CorMedix Therapeutics announced interim results from a real-world evidence study of DefenCath, showing significant reductions in catheter-related bloodstream infections (CRBSI) and related hospitalizations in hemodialysis patients [1][3]. Company Overview - CorMedix is a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases, particularly through its product DefenCath, aimed at preventing CRBSI in adult hemodialysis patients [5][6]. - The company has expanded its portfolio following the acquisition of Melinta Therapeutics LLC, which includes various anti-infective products [5][6]. Study Details - The real-world evidence study, initiated in July 2024, aims to assess the impact of DefenCath on CRBSI rates and hospitalizations over a two-year period, with over 3,000 patients currently using the product monthly at U.S. Renal Care facilities [2][3]. - Preliminary analysis indicates a 72% reduction in CRBSI and a 70% reduction in hospitalizations due to CRBSI compared to historical controls, highlighting the potential cost savings for the healthcare system [3]. Economic Impact - The Centers for Medicare & Medicaid Services (CMS) spends over $3 billion annually on CRBSI-related costs in the end-stage renal disease (ESRD) patient population, with average hospitalization costs estimated at $63,000, potentially rising to $110,000 per incident [3]. - CorMedix aims to leverage these findings in discussions with payers, including Medicare Advantage, to enhance access to DefenCath and establish long-term reimbursement strategies [4]. Future Directions - The company is also assessing secondary data points such as missed treatment sessions and antibiotic utilization, with plans to release additional real-world evidence data in the future [4]. - CorMedix continues to conduct clinical studies for DefenCath in other patient populations and intends to develop it as a catheter lock solution [7].